United-Guardian, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; comparisons are with fiscal 2019. This is an annual filing, and the supplied text does not provide separate fourth-quarter results. The company manufactures cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products through its Guardian Laboratories division.
Financial performance and position
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Net sales | $10.99 million | $13.60 million | Down 19% |
| Gross profit margin | 56% | 58% | Down 2 percentage points |
| Operating income | $3.64 million | $5.40 million | Down 33% |
| Net income | $3.30 million | $4.76 million | Down 31% |
| Basic and diluted EPS | $0.72 | $1.04 | Down $0.32 |
| Cash from operations | $3.59 million | $4.48 million | Down 20% |
- Sales by category: cosmetic ingredients $4.27 million, down 33%; pharmaceuticals $4.52 million, up 10%; medical products $2.05 million, down 31%; industrial and other $139,482, down 13%.
- Renacidin represented about 36% of sales, versus 26% in 2019; Lubrajel products represented about 57%, versus 67%. The company’s two major product lines together accounted for about 92% of sales.
- Operating expenses fell to $2.03 million from $2.15 million; research and development expense rose to $451,208 from $397,391. Investment income increased to $226,245, while net gains on marketable securities declined to $298,585 from $431,076.
- At year-end, cash and cash equivalents were $591,444 and marketable securities were $7.59 million. Working capital was $9.83 million, down from $10.22 million; the current ratio was 8.0, versus 8.6. The balance sheet reports no borrowings or other debt.
- Cash used in financing was $3.58 million, all dividends, compared with $5.05 million in 2019. Dividends declared were $0.78 per share in 2020, versus $1.10 in 2019.
Material changes and management commentary
- COVID-19 disrupted demand and manufacturing in China and contributed to excess channel inventory, sharply reducing cosmetic ingredient sales, particularly sales through Ashland Specialty Ingredients (ASI). The company also attributed weaker medical product orders partly to the pandemic and the loss of a major customer.
- Pharmaceutical sales were not materially affected by the pandemic. Renacidin sales increased, which the company attributed partly to expanded internet advertising and its dedicated website.
- Lower sales of higher-margin Lubrajel products and a greater share of lower-margin Renacidin sales contributed to the gross-margin decline.
- The company ended participation in the Medicaid Drug Rebate and 340B programs effective December 31, 2020, concluding that the rebates made participation unprofitable. It continues to participate in the VA Federal Supply Schedule and Medicare Part D Coverage Gap Discount Program.
- Management expects pandemic-related pressure on cosmetic ingredient sales to continue through most or all of 2021, but said it could not reliably estimate the pandemic’s overall future financial impact. It expected 2021 operating expenses to remain relatively consistent and R&D expense to be comparable to 2020.
- Management identified several cosmetic product development projects and anticipated introducing several new products in 2021, while cautioning that development-stage projects may not become commercially successful. Management also reported qualifying for the Employee Retention Credit in first-quarter 2021 and expected to use it to support liquidity.
Risks, contingencies, and unusual items
- Sales and receivables are concentrated: four distributors and marketing partners accounted for approximately 72% of gross sales and 67% of year-end receivables. ASI alone accounted for about 29% of company sales. The company also relies on six major suppliers for about 88% of raw material purchases.
- Lower-priced competitors, especially Asian competitors, continue to pressure cosmetic product pricing and margins. The company’s exposure to China, customer ordering patterns, and distributor inventory add uncertainty to recovery.
- Marketable securities are a significant share of current assets; the company reported $298,585 of 2020 net gains, including a $117,010 unrealized loss on securities still held at year-end. Management recorded no impairment charge.
- The company reported no legal proceedings, material capital commitments, or off-balance-sheet arrangements. It reported effective disclosure controls and internal control over financial reporting based on management’s assessment; the auditor did not provide an internal-control attestation. The independent auditor reported no critical audit matters.
Important facts for investors to verify
- Whether cosmetic sales, especially ASI-linked China sales, recover as channel inventory normalizes and pandemic conditions ease.
- The effect of exiting Medicaid and 340B on Renacidin demand, net pricing, rebates, and profitability, alongside continued VA and Medicare program obligations.
- Whether medical product sales stabilize after customer losses and pandemic-related order reductions.
- The performance, valuation, and risk profile of the marketable securities portfolio and the sustainability of investment-related income and gains.
- Whether new product launches and development projects generate meaningful sales, and whether dividends remain sustainable relative to earnings and operating cash flow.